Fragment-based Approaches in Drug Discovery - Hardcover

9783527312917: Fragment-based Approaches in Drug Discovery

Hardcover

ISBN 10: 3527312919 ISBN 13: 9783527312917

Publisher: Wiley-VCH, 2006

This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.

"synopsis" may belong to another edition of this title.

From the Back Cover:

Based on recent successes in the modular design of pharmaceutically active ligands, the concept and technology of fragment-based design has quickly pervaded the research departments of pharma companies, large and small. Drug developers everywhere are currently struggling to keep ahead of the competition by applying these methods to speed up the drug discovery.
This first systematic summary of the impact of such approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this book by professionals for professionals is indispensable for drug developers in the pharma and biotech sector who need to keep abreast of the latest technologies and strategies in pharmaceutical ligand design. Clearly divided into sections on ligand design, spectroscopic techniques, and screening and drug discovery, the text is backed by numerous case studies.

About the Author:

Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU M�nchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.

"About this title" may belong to another edition of this title.